AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KAUG 66 min read$DCTH

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DCTH
Bullish
high confidence
Mentioned
$DCTH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DCTHBullishMed
01

Why it matters

Traders can reprice DCTH based on the raised 2026 revenue range ($104M-$108M) and the stated driver of at least 28% HEPZATO KIT volume growth over 2025, alongside Q2 operating cash flow and cash balance.

02

Market read

A company-specific earnings and guidance update with explicit full-year revenue and margin ranges, plus operational metrics (treatment centers, HEPZATO volume growth).

03

What to watch

R&D and SG&A both rose in Q2, and the filing does not provide updated trial endpoints beyond dosing and retrospective presentations, which may limit upside if investors demand prospective efficacy data.

Relevance 7/10Novelty 8/10Timing: filed pre-market today, guidance and Q2 results digest immediately

Background

SEC 8-K Item 2.02 with Exhibit 99.1 covering Delcath’s Q2 2026 results, business highlights, and full-year 2026 financial guidance.

Company-level read

Ticker impact

$DCTHBullishHigh confidence
Context

Delcath reported Q2 revenue of $29.1M, raised 2026 guidance to $104M-$108M, and reiterated positive adjusted EBITDA outlook.

Expected impact

Likely positive bias for the next session and into guidance digestion, with focus on whether HEPZATO volume growth sustains.

Evidence & confidence

The filing discloses fresh, decision-relevant numbers: Q2 revenue and margins, cash balance, and a full-year revenue range tied to at least 28% HEPZATO KIT volume growth over 2025.

Market effects

Sector

Reinforces investor appetite for interventional oncology and liver-directed delivery platforms, potentially supporting peer sentiment.

Regional

Primarily US small-cap biotech sentiment; limited direct regional spillover beyond healthcare.

Global

Europe device revenue contribution is mentioned, but the disclosed catalyst is company-specific rather than global policy or trial readout.

Counterpoint

What could challenge this read

Adjusted EBITDA declined year over year (to $7.6M from $9.8M), so the market may question whether guidance relies on volume growth that is not yet translating into profitability.

Key entities

  • company
    Delcath Systems, Inc.

    Interventional oncology company reporting Q2 2026 results and raising full-year 2026 revenue guidance.

  • product
    HEPZATO KIT

    Primary revenue driver in the US, with reported Q2 revenue of $27.1M and guidance tied to volume growth.

  • product
    CHEMOSAT

    Europe revenue contributor, with reported Q2 revenue of $2.0M.

Read at source← All news

Related articles

OCT 19
$DCTHMedAI 8/10

Delcath Systems, Inc.: Delcath Systems Highlights Clinical Program Presentations at ESMO Congress 2026 and Independent Data on Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Delcath Systems (DCTH) announced presentations at ESMO Congress 2026, including updates on its Phase 2 trials for metastatic colorectal and breast cancer. Independent data on its CHEMOSAT system for liver-dominant metastatic uveal melanoma showed a 66.7% objective response rate and 28-month median overall survival. The company focuses on liver cancer treatments with its HEPZATO KIT and CHEMOSAT systems.

finanznachrichten.de2 min
OCT 19
$DCTHMedAI 8/10

An independent analysis found a 66.7% response rate in 12 patients treated for melanoma spread to the liver.

An independent analysis of 12 patients with liver-metastatic uveal melanoma treated with melphalan hepatic delivery (PHP) and ipilimumab/nivolumab reported a 66.7% response rate and 75% disease control rate. The median overall survival was 28 months. Delcath Systems, Inc. is presenting clinical trial updates at ESMO Congress 2026, including data on its HEPZATO KIT and CHEMOSAT systems for liver-directed chemotherapy.

stocktitan.net2 min
SEP 11
$DCTHMed

Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost

Delcath Systems (DCTH) reported Q2 revenue of $29.1M, up from $24.2M YoY, driven by its HEPZATO KIT and CHEMOSAT devices. The company raised its 2026 revenue guidance to $104M-$108M. However, expenses rose, with R&D and SG&A increasing, leading to flat net income. Delcath has $95.9M in cash and no debt, and is expanding into new indications.

insidermonkey.com3 min
JUL 9
$DCTHMed

Delcath Systems, Inc.: Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Breast Cancer

Delcath Systems (Nasdaq: DCTH) said the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO plus standard of care versus standard of care alone for liver-dominant HER2-negative metastatic breast cancer. The randomized study will enroll about 90 patients at 20+ sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.

finanznachrichten.de3 min
OCT 19
$WALMedAI 8/10

Western Alliance Bancorp (WAL) Q3 Earnings Beat EPS Estimates De

Western Alliance Bancorp (WAL) reported Q3 2026 earnings with EPS of $2.45, beating estimates, but revenue was $1.01B and deposits fell to $81.76B. The company's P/S ratio is 2.09, below its historical median. Insiders have sold more shares than they've bought. WAL has a GF Score of 89/100, indicating strong growth and profitability but weak financial strength.

gurufocus.com3 min